Description
Book SynopsisThis fully updated volume explores recently improved avenues to study urothelial carcinomas.
Table of ContentsPart I: Molecular Characterization
1. Scoring Systems for Immunohistochemistry in Urothelial Carcinoma
Mark-Sebastian Bösherz, Iryna V. Samarska, and Nadine Therese Gaisa
2. A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer
Csilla Olah and Tibor Szarvas
3. Analysis of Mutational Signatures Using the mutSignatures R Library
Damiano Fantini and Joshua J. Meeks
4. A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures
Marika Mokou, Shaman Narayanasamy, Rafael Stroggilos, Irina-Afrodita Balaur, Antonia Vlahou, Harald Mischak, and Maria Frantzi
5. Characterization of Native COMPASS Complex in Urothelial Carcinoma Cells by Size Exclusion Chromatography Christoph Peter, Wolfgang A. Schulz, and Patcharawalai Whongsiri
Part II: Urothelial Carcinogenesis
6. Reconstructing Phylogenetic Relationship in Bladder Cancer: A Methodological Overview
Lancelot Seillier and Martin Peifer
7. Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells
Theodoros Rampias and Apostolos Klinakis
8. Identification of STAG2 Mutant Bladder Cancers by Immunohistochemistry
Youngrok Park, Alana Lelo, Brent Harris, Deborah L. Berry, Krysta Chaldekas, Jung-Sik Kim, and Todd Waldman
Part III: Cellular and Animal Models
9. Genome-Wide CRISPR Screening for the Identification of Therapy-Resistance-Associated Genes in Urothelial Carcinoma
Klaus Mantwill and Roman Nawroth
10. Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma
William Donelan, Paul L. Crispen, and Sergei Kusmartsev
Part IV: Biomarkers
11. NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA
Iver Nordentoft, Karin Birkenkamp-Demtröder, and Lars Dyrskjøt
12. Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-Muscle Invasive Bladder Cancer
Thorsten H. Ecke, Natalya Benderska-Söder, Ekkehardt Bismarck, Bas W.G. van Rhijn, Tilman Todenhöfer, and Bernd J. Schmitz-Dräger
13. Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-Invasive Diagnosis of Urothelial Cancer
Maria Zvereva, Md Ismail Hosen, Nathalie Forey, Mahdi Sheikh, Caroline Kannengiesser, Ibrahima Ba, Arnaud Manel, Emmanuel Vian, and Florence Le Calvez-Kelm
14. Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer
Jussi Nikkola and Peter Black
15. Assessment of PD-L1 Status in Urothelial Cancer
Veronika Bahlinger, Arndt Hartmann, and Markus Eckstein
Part V: Therapy Development
16. Epigenetic Priming and Development of New Combination Therapy Approaches
Sarah Meneceur, Camilla M. Grunewald, Günter Niegisch, and Michèle. J. Hoffmann
17. Evaluation of FGFR Alteration Status in Urothelial Tumors
Veronika Bahlinger, Markus Eckstein, Arndt Hartmann, and Robert Stöhr
18. Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma
Günter Niegisch
19. Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer
Paola Grandi, Andrea Darilek, Anay Moscu, Anu Pradhan, and Roger Li
20. Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21
Kate Relph, Mehreen Arif, Hardev Pandha, Nicola Annels, and Guy R. Simpson
